<DOC>
	<DOCNO>NCT02462837</DOCNO>
	<brief_summary>The objective pilot study ass whether Myrbetriq™ improve post-operative ureteral pain discomfort , reduce bladder storage symptom increase quality life follow ureteral stenting .</brief_summary>
	<brief_title>Myrbetriq™ ( Mirabegron ) Reduce Pain Discomfort Following Ureteral Stent Placement</brief_title>
	<detailed_description />
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>1 . Age ≥ 18 . 2 . Subject schedule undergo ureteral stent placement ureteral obstruction post ureteroscopy procedure . 3 . Otherwise healthy subject able willing participate study . 4 . None plan intervention document labeled contraindication , warning precaution study drug . 1 . Does NOT give consent . 2 . Subject use prohibited medication stop safely screen visit . Subject exclude use restrict medication meet protocolspecified criterion : ( ) Phytotherapy BPH 5alpha reductase inhibitor within 3 month , persistent urinary symptom AUASS 7 . ( ii ) Taken oral alpha agonist , anticholinergic cholinergic medication within 5 day first screen visit follow exception ( ) : singular dose give ER hospital floor prior procedure , topical anticholinergic eye drop use glaucoma inhale anticholinergic use COPD . ( iii ) Taken tricyclic antidepressant within 2 week first screen visit . ( iv ) Taken estrogen , androgen , drug produce androgen suppression , anabolic steroid within 3 month follow exception : topical cream local treatment . 3 . Post void residual volume &gt; 350 mL . 4 . Female subject breastfeeding , pregnant , intend become pregnant study , childbearing potential sexually active practice highly reliable method birth control . 5 . Subject know neurogenic bladder . 6 . Subject uncontrolled chronic pain problem chronic pain medication . 7 . Subject significant stress incontinence mixed stress/urgency incontinence stress predominant factor determine investigator ( female subject confirm cough provocation test ) . 8 . Subject indwell catheter practice intermittent selfcatheterization . 9 . Known primary neurologic condition multiple sclerosis , Parkinson 's disease , diabetic neuropathy neurological disease know affect bladder function . 10 . Subject evidence symptomatic active urinary tract infection , chronic inflammation interstitial cystitis , previous pelvic radiation therapy previous current malignant disease pelvic organ , bladder stone ( locate different anatomical location cause LUTS similar bladder infection pain related location bladder could mask treatment effect ) . 11 . Subject currently active treatment botulinum toxin ( bladder paralytic ) intravesically . 12 . Subject moderate severe hepatic impairment [ ALT ( SGPT ) AST ( SGOT ) value great 3 time upper limit normal clinical center lab ; confirm second measurement ] . 13 . Subject severe renal impairment End Stage Renal disease ( i.e. , creatinine great 2.0 mg/dl ) . 14 . Subject severe uncontrolled hypertension ( define systolic blood pressure ≥180mmHg /or diastolic pressure ≥ 110mmHg ) . 15 . Subject clinically significant abnormal ECG chart know history QT prolongation currently take medication know prolong QT interval . Any patient taking Digoxin . 16 . Subject know suspected hypersensitivity Mirabegron inactive ingredient . 17 . Subject concurrent genitourinary malignancy , active cancer ( except noninvasive skin cancer ) within last 5 year prior screen . Men history prostate cancer regardless curability eligible . 18 . Subject treat experimental device within 30 day receive experimental agent within long 30 day five halflives . 19 . Unable follow protocol direction due organic brain psychiatric disease . 20 . Intraoperative complication require hospital admission . 21 . History alcoholism substance abuse , , opinion investigator , would affect compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Ureteral Stents</keyword>
	<keyword>Pain Discomfort</keyword>
	<keyword>Bladder Storage Symptoms</keyword>
</DOC>